In summary, our study reveals that HHLA2 enhances c-Met phosphorylation, driving HCC progression, and demonstrates that HHLA2 levels, detectable in patient serum, can potentially serve as a liquid biopsy marker to predict the efficacy of c-Met inhibitor treatment in HCC. The gene discussed is MET; the disease is hepatocellular carcinoma.